Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
Abstract Background PD-1 blockade plus chemotherapy has become the first-line standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without oncogenic drivers. Oncogenic-driven advanced NSCLC showed limited response to PD-1 blockade monotherapy or chemotherapy alone. Whether...
Saved in:
Main Authors: | Haowei Wang, Lei Cheng, Jian Chen, Peixin Chen, Zhuoran Tang, Qianyi Wang, Ying Ma, Chao Zhao, Xuefei Li, Tao Jiang, Fei Zhou, Xiaoxia Chen, Caicun Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-02-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-024-03937-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer
by: Lulu Zhang, et al.
Published: (2025-02-01) -
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01) -
Transcriptomic landscape of Hras12V oncogene-induced hepatocarcinogenesis with gender disparity
by: Huaiyuan Di, et al.
Published: (2025-01-01) -
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
by: Maximilian Kramer‐Drauberg, et al.
Published: (2025-02-01) -
Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)